RxDoctor Payments Data

Paige Davis

Acute Care · Rogers, ARNPI 1013447846

Payments from drug & device makers

$1,893in general payments, 2019–2025

Across 96 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$455
  • Phathom Pharmaceuticals, Inc.$355
  • Johnson & Johnson$198
  • Merz North America, Inc.$117
  • Ipsen Biopharmaceuticals, Inc$108
  • Sanofi$107
  • plus $553 from 13 others

What the payments were for

  • Food & beverage$1,86699%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,893 in reported general payments places this provider in the 80th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas

Medicare billing

Part B allowed, 2024
$29,589
Medicare patients
229
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide28$27,749
CreonLipase/Protease/Amylase19$27,145
Colestipol Hcl95$4,830
Budesonide DrBudesonide27$4,561
Pantoprazole Sodium309$3,294
Omeprazole150$2,717
Sucralfate51$2,510
Famotidine145$1,433
Lubiprostone17$1,220
Mirtazapine23$708
Amitriptyline Hcl47$306
Ondansetron OdtOndansetron14$224
Dicyclomine Hcl11$73
Gabapentin16$69
Metoclopramide Hcl12$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$455$54,89347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 321 acute care providers in Arkansas.

Other acute care in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →